{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:12:43Z","timestamp":1783606363029,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Small intestinal metastasis from primary breast cancer remains a rare clinical occurrence. Despite extensive research into its clinicopathological features and treatment options, the specific pathogenesis and optimal management strategies remain incompletely understood. This case report presents a patient with breast cancer that metastasized to the small intestine. The primary breast tumor was diagnosed as classic invasive lobular carcinoma. Subsequent surgical intervention successfully addressed the intestinal obstruction and confirmed the metastatic origin of the small intestinal tumor. Interestingly, the metastatic lesions exhibited features suggestive of pleomorphic lobular carcinoma. A PET-CT scan was performed to evaluate the distant metastasis status of this patient. Notably, hormonal receptor status shifted from positive to negative, while HER2 expression changed from negative to low between the primary tumor and metastatic lesions. The presence of an undiagnosed pleomorphic component in the primary tumor might explain the disease\u2019s progressive nature. In this case, systemic treatment with trastuzumab deruxtecan yielded favorable therapeutic outcomes. Overall, our findings suggest that re-evaluation of receptor status in breast cancer metastases is crucial for tailoring treatment strategies. Furthermore, a combination of palliative resection of small intestinal metastases and targeted therapy for HER2-low breast cancer may potentially improve survival.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1475018","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:22:18Z","timestamp":1733199738000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Small intestinal metastasis from primary breast cancer: a case report and review of literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Fengqing","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanlu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1288077","article-title":"Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments","volume":"13","author":"Qiu","year":"2023","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.3390\/ijms23126806","article-title":"Breast cancer metastasis: mechanisms and therapeutic implications","volume":"23","author":"Park","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1186\/s12967-024-05531-x","article-title":"Leveraging the intratumoral microbiota to treat human cancer: are engineered exosomes an effective strategy","volume":"22","author":"Qiu","year":"2024","journal-title":"J Trans Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/00031348231173979","article-title":"Breast cancer metastasis to colon","volume":"89","author":"Arif","year":"2023","journal-title":"Am Surgeon"},{"key":"B5","article-title":"Breast cancer and gastrointestinal metastasis. A case report and review of the literature","volume":"89","author":"Invento","year":"2018","journal-title":"Annali Italiani di Chirurgia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.900832","article-title":"Case Report: Small intestinal metastatic breast cancer: A case report and literature review","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2010.01.013","article-title":"Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma","volume":"46","author":"Dwivedi","year":"2010","journal-title":"Oral Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2023.2220938","article-title":"Immunotherapy in small bowel adenocarcinoma: a potential role","volume":"47","author":"Vitiello","year":"2024","journal-title":"Immunol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i39.5658","article-title":"Risk factors for small intestinal adenocarcinomas that are common in the proximal small intestine","volume":"28","author":"Fujimori","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S180949","article-title":"Intestinal metastasis from breast invasive ductal carcinoma after a long latency: case report and literature review","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619858211","article-title":"Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice","volume":"7","author":"Legu\u00e9","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v113:8","article-title":"Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma","volume":"113","author":"Overman","year":"2008","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1171-7","article-title":"Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994-2010: a population-based study","volume":"51","author":"Bojesen","year":"2016","journal-title":"J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s11523-019-00681-1","article-title":"Addition of bevacizumab to first-line palliative chemotherapy in patients with metastatic small bowel adenocarcinoma: A population-based study","volume":"14","author":"Legu\u00e9","year":"2019","journal-title":"Targeted Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e230631","DOI":"10.1001\/jamanetworkopen.2023.0631","article-title":"Evaluation of systemic treatments of small intestinal adenocarcinomas: A systematic review and meta-analysis","volume":"6","author":"de Back","year":"2023","journal-title":"JAMA Network Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e22093","DOI":"10.1016\/j.heliyon.2023.e22093","article-title":"Targeting SIRT1 synergistically improves the antitumor effect of JQ-1 in hepatocellular carcinoma","volume":"9","author":"Jiang","year":"2023","journal-title":"Heliyon"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101860","DOI":"10.1016\/j.bpg.2023.101860","article-title":"Updates in the diagnosis and management of small-bowel tumors","author":"Vlachou","year":"2023","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i28.4738","article-title":"HER2-positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum: A case report","volume":"27","author":"Hirokawa","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-019-0798-2","article-title":"Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives","volume":"12","author":"Krasniqi","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.v42.10","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun (London England)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1158\/2159-8290.CD-NB2022-0043","article-title":"T-DXd: new standard for HER2-low breast cancer","volume":"12","year":"2022","journal-title":"Cancer Discovery"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.003","article-title":"Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11864-024-01183-7","article-title":"HER2-positive metastatic colorectal cancer","volume":"25","author":"Robinson","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10549-017-4645-2","article-title":"GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer","volume":"169","author":"Ni","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000186","article-title":"The novel marker GATA3 is significantly more sensitive than traditional markers mammaglobin and GCDFP15 for identifying breast cancer in surgical and cytology specimens of metastatic and matched primary tumors","volume":"24","author":"Sangoi","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol: AIMM"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: A systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0350","article-title":"Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis","volume":"18","author":"Curtit","year":"2013","journal-title":"Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05746-8","article-title":"Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer","volume":"183","author":"Walter","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/JOC.JOC_117_18","article-title":"Hormone receptors and human epidermal growth factor (HER2) expression in fine-needle aspirates from metastatic breast carcinoma - role in patient management","volume":"36","author":"Francis","year":"2019","journal-title":"J\u00a0Cytol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.03.030","article-title":"Breast cancer: presentation and intervention in women with gastrointestinal metastasis\u00a0and carcinomatosis","volume":"12","author":"McLemore","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13333","article-title":"Metastatic invasive lobular breast cancer presenting as linitis plastica of the colon: Tumour characterization using [(18) F]FES PET\/MRI","volume":"66","author":"Tsujikawa","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41379-020-00689-3","article-title":"Lobular carcinoma in situ: diagnostic criteria and molecular correlates","volume":"34","author":"Sokolova","year":"2021","journal-title":"Modern Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i5.382","article-title":"Intestinal metastasis from breast cancer: Presentation, treatment and survival from a systematic literature review","volume":"12","author":"Bolzacchini","year":"2021","journal-title":"World J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1475018\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:22:22Z","timestamp":1733199742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1475018\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2024.1475018"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1475018","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"article-number":"1475018"}}